Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71.
Qiu X, Shen C, Zhao W, Zhang X, Zhao D, Zhu Y, et al. Prognostic value of the combination of HB (hemoglobin) and CEA in resectable gastric cancer. J Cancer. 2022;13:2246–57.
Article PubMed PubMed Central Google Scholar
Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250–60.
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.
Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011;71:1367–84.
Hashimoto T, Kurokawa Y, Mori M, Doki Y. Update on the treatment of gastric cancer. JMA J. 2018;1:40–9.
Article PubMed PubMed Central Google Scholar
Wang Y, Zhang L, Yang Y, Lu S, Chen H. Progress of gastric cancer surgery in the era of precision medicine. Int J Biol Sci. 2021;17:1041–9.
Article PubMed PubMed Central Google Scholar
Shen L, Xu JM, Feng FY, Jiao SC, Wang LW, Li J, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport. Zhonghua Zhong Liu Za Zhi. 2013;35:295–300.
Nord K, Nilsson J, Nilsson B, Uhlen M, Nygren PA. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 1995;8:601–8.
Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol. 1997;15:772–7.
Fedorova A, Zobel K, Gill HS, Ogasawara A, Flores JE, Tinianow JN, et al. The development of peptide-based tools for the analysis of angiogenesis. Chem Biol. 2011;18:839–45.
Stahl S, Graslund T, Eriksson Karlstrom A, Frejd FY, Nygren PA, Lofblom J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35:691–712.
Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670–80.
Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel. 2004;17:455–62.
Antaris AL, Chen H, Cheng K, Sun Y, Hong G, Qu C, et al. A small-molecule dye for NIR-II imaging. Nat Mater. 2016;15:235–42.
Cai Y, Ren J, Jin J, Shao H, Wang P, Cheng K, et al. Novel affibody molecules as potential agents in molecular imaging for MAGE-A3-positive tumor diagnosis. Environ Res. 2023;237: 116895.
Xue X, Wang B, Du W, Zhang C, Song Y, Cai Y, et al. Generation of affibody molecules specific for HPV16 E7 recognition. Oncotarget. 2016;7:73995–4005.
Article PubMed PubMed Central Google Scholar
Zhu S, Zhu J, Song Y, Chen J, Wang L, Zhou M, et al. Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer. Appl Microbiol Biotechnol. 2018;102:7429–39.
Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14:769–85.
Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature. 1995;373:623–6.
Mukherjee SK, Wilhelm A, Antoniades CG. TAM receptor tyrosine kinase function and the immunopathology of liver disease. Am J Physiol Gastrointest Liver Physiol. 2016;310:G899-905.
Article PubMed PubMed Central Google Scholar
Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, et al. Structural basis for Gas6-Axl signalling. EMBO J. 2006;25:80–7.
Braunger J, Schleithoff L, Schulz AS, Kessler H, Lammers R, Ullrich A, et al. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene. 1997;14:2619–31.
Scaltriti M, Elkabets M, Baselga J. Molecular pathways: AXL, a membrane receptor mediator of resistance to therapy. Clin Cancer Res. 2016;22:1313–7.
Article PubMed PubMed Central Google Scholar
Dent P. Crosstalk between ERK, AKT, and cell survival. Cancer Biol Ther. 2014;15:245–6.
Article PubMed PubMed Central Google Scholar
Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer. 2017;116:415–23.
Article PubMed PubMed Central Google Scholar
Huang H, Liu H, Yan R, Hu M. PI3K/Akt and ERK/MAPK signaling promote different aspects of neuron survival and axonal regrowth following rat facial nerve axotomy. Neurochem Res. 2017;42:3515–24.
Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J, et al. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer. Clin Cancer Res. 2017;23:6239–53.
Article PubMed PubMed Central Google Scholar
Zhu C, Shi H, Wu M, Wei X. A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment. MedComm. 2020;2020(1):103–18.
Bae CA, Ham IH, Oh HJ, Lee D, Woo J, Son SY, et al. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. Gastric Cancer. 2020;23:824–36.
Kashyap MK, Abdel-Rahman O. Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Mol Cancer. 2018;17:54.
Article PubMed PubMed Central Google Scholar
Kim TH, Lee D, Oh HJ, Ham IH, Lee DM, Lee Y, et al. Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer. Life Sci. 2023;335: 122230.
Adam-Artigues A, Arenas EJ, Arribas J, Prat A, Cejalvo JM. AXL - a new player in resistance to HER2 blockade. Cancer Treat Rev. 2023;121: 102639.
Atreya R, Goetz M. Molecular imaging in gastroenterology. Nat Rev Gastroenterol Hepatol. 2013;10:704–12.
Zhou Z, Lu ZR. Molecular imaging of the tumor microenvironment. Adv Drug Deliv Rev. 2017;113:24–48.
Comments (0)